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Objectives: Health systems face nonfinancial constraints that can influence the opportunity cost of interventions. Empirical
methods to explore their impact, however, are underdeveloped. We develop a conceptual framework for defining health
system constraints and empirical estimation methods that rely on routine data. We then present an empirical approach for
incorporating nonfinancial constraints in cost-effectiveness models of health benefit packages for the health sector.
Methods:We illustrate the application of this approach through a case study of defining a package of services for tuberculosis
case-finding in South Africa. An economic model combining transmission model outputs with unit costs was developed to
examine the cost-effectiveness of alternative screening and diagnostic algorithms. Constraints were operationalized as
restrictions on achievable coverage based on: (1) financial resources; (2) human resources; and (3) policy constraints
around diagnostics purchasing. Cost-effectiveness of the interventions was assessed under one “unconstrained” and
several “constrained” scenarios. For the unconstrained scenario, incremental cost-effectiveness ratios were estimated with
and without the costs of “relaxing” constraints.
Results: We find substantial differences in incremental cost-effectiveness ratios across scenarios, leading to variations in the
decision rules for prioritizing interventions. In constrained scenarios, the limiting factor for most interventions was not
financial, but rather the availability of human resources.
Conclusions: We find that optimal prioritization among different tuberculosis control strategies in South Africa is influenced
by whether and how constraints are taken into consideration. We thus demonstrate both the importance and feasibility of
considering nonfinancial constraints in health sector resource allocation models.
Keywords: health system constraints, model-based economic evaluation, priority setting.
VALUE HEALTH. 2020; -(-):-–-Introduction
Health sectors face nonfinancial constraints that prevent the
efficient allocation of resources. Nonfinancial constraints have
consequences for the assessment of cost-effectiveness because
they can influence the opportunity cost of new interventions and
technologies.1,2 Supply-side (or health systems) nonfinancial
constraints occur when factors of production (inputs) are “fixed”
in the short run, either owing to physical and external barriers (for
example, it may take 5 years to train health professionals, there
may be political barriers to immigration, or “sunk” costs in oper-
ating theaters may prevent use of funds to expand outpatient
facilities), or owing to health sector actors deliberately con-
straining resource availability/flexibility through policy decisions
(for example, accreditation systems restricting the supply of
clinical labor, or budgeting and procurement practices). Whatever
their nature, nonfinancial constraints ultimately impact the healthss correspondence to Fiammetta M. Bozzani, 15-17 Tavistock Place, WC1H 9
15 - see front matter Copyright ª 2020, ISPOR–The Professional Society for
cess article under the CC BY license (http://creativecommons.org/licenses/bsector’s ability to react to technological change by “fixing” the
levels and use of specific sets of inputs, and consequently, in the
short run, new technologies dependent on these inputs may have
higher opportunity costs than they would if all inputs were
variable.
Van Baal and colleagues have previously presented both a
theoretical and an empirical approach for estimating the extent to
which nonfinancial constraints affect opportunity costs.1 They
characterize the decision under two separate constraints: one for
the general budget and one for the constrained input; they
recognize that the constrained input has a lower cost-
effectiveness threshold (k1) than the unconstrained input (k0),
which reflects its higher opportunity cost, so that k1 , k0. The
traditional decision rule, comparing the incremental cost per unit
of health produced by the intervention to the general opportunity
cost threshold, can thus be modified by adjusting the opportunity
cost of the constrained input by the ratio k0k1.SH, London, England, United Kingdom. Email: fiammetta.bozzani@lshtm.ac.uk
Health Economics and Outcomes Research. Published by Elsevier Inc. This is an
y/4.0/).
2 VALUE IN HEALTH - 2020Empirically, van Baal and colleagues posit that the relative
costs of constrained to nonconstrained inputs per unit of outcome
in the current standard of care reflect their relative current op-
portunity cost. Assuming constant returns to scale and perfectly
divisible inputs, they provide a 2-intervention, 2-input model:
k0
k1
¼ s2t
q2p
(1)
where s and t denote the unit costs of interventions i and j, while q
and p denote the costs of the constrained inputs for the same
interventions, respectively.1
This approach can be used to empirically correct for downward
bias in incremental cost-effectiveness ratios (ICERs) of new tech-
nologies implemented in health systems where specific inputs are
constrained (or upward bias in rarer cases of existing spare ca-
pacity in the system), and where data are available on both the
cost of the intervention and standard of care divided into con-
strained and unconstrained inputs. In principle, this approach
could also be extended to within health sector budget constraints,
for example, when dealing with fixed budgets for different disease
programs. In this case, groups of disease-specific inputs have a
higher opportunity cost than spending on other areas of the health
system. Potentially, once the comparative cost per health outcome
is known for each program, the incremental cost-effectiveness of
the program may be adjusted using the same approach.
Based on an application by Revill and colleagues, this approach
appears empirically feasible.3 It has several limitations, however,
that can be grouped into 2 sets: one that restricts its applicability
to certain settings and another that questions its underlying as-
sumptions. First, in many low- and middle-income countries
(LMICs) there remains a substantial empirical challenge in
deriving cost estimates. Given data scarcity on the relationship
between costs, outputs, and outcomes, it is unlikely that decision
makers are sufficiently informed for costs to represent current
relative opportunity costs of inputs. Another setting-specific lim-
itation is that the approach relies on the estimation of health
sector opportunity cost-based thresholds, which add substantial
uncertainty. With regard to the more general limitations, the
assumption of constant returns to scale for inputs is only likely to
hold for some inputs. Moreover, as it stands, the approach pro-
posed by van Baal and colleagues and its subsequent application
do not present the decision maker with a choice set that includes
relaxing nonfinancial constraints.Empirical Approaches
Decision makers prioritizing new technologies (or packages of
interventions across specific disease areas) often do not have
control over decisions made around the wider health system
constraints. For example, the manager of a human immunodefi-
ciency virus (HIV) program may be able to decide to invest in a
new HIV treatment but may not be able to determine the overall
level of nurses available in the health sector. Ideally, when the
supply of nurses is constrained, the HIV program would prioritize
interventions with a lower demand on nurses than it would in the
absence of constraints. Alternatively, program managers may
consider cofinancing interventions that relax the overall nursing
constraints, although this rarely happens in practice.4
Methods to support priority setting for investment in infec-
tious disease programs are evolving and receiving increased aca-
demic attention. The widespread use of mathematical modeling in
economic evaluation for infectious disease interventions has
enabled optimization among multiple interacting intervention
options under a disease-specific budget constraint.5,6 Currently,these models estimate the costs of interventions and comparators
by multiplying services produced by their average cost or, in some
cases, employing a cost function.7,8 We present an empirical
method that builds on the strengths of these models. Our
approach has 4 stages: (1) consulting decision makers to elicit
nonfinancial constraints applicable to the specific setting and in-
terventions of interest; (2) quantifying the constraints and their
impact; (3) employing economic evaluation models (in this case
mathematical models) to estimate costs and quantities of con-
strained inputs; (4) producing ICERs both with and without con-
straints. We illustrate the importance and feasibility of our
method through a case study, conducted using secondary and
routine data within a policy-led (national strategic planning) time
frame.
Methods
Case Study Setting and Interventions
Tuberculosis (TB) control is a major concern for the South Af-
rican health system.9 In 2015, plans were announced for a
comprehensive TB screening program, a component of which in-
volves using intensified case finding (ICF) to screen every person
attending a public health facility for any reason. Initial (conven-
tional) mathematical modeling of the potential impact found that
scale-up of ICF to all health facility attendees is the single most
effective intervention for reaching the post-2015 global TB tar-
gets,10 but is also the costliest screening option.11 Policy makers in
South Africa, however, were concerned about the feasibility of
implementing such a complex intervention at full scale in a health
system that they felt was “overstretched.” As part of the National
Strategic Plan (2017-2022) priority-setting process, we therefore
reassessed ICF policy options incorporating supply-side health
system constraints, adding a measure of the feasibility of these
options in terms of the costs of relieving the constraints.
Strategies to identify and treat people with TB, especially those
who have not sought diagnostic services on their own initiative,
have the potential to become an integral part of TB control in
LMICs, where access to health services is poor, even among
symptomatic patients, and there is limited capacity among health
providers to recognize symptoms.12 ICF, or facility-based
screening, was adopted in South Africa for detecting TB cases
among HIV clinic attendees, who are screened for TB at each visit.
The TB program, though, still relies on “passive case-finding,”
screening only those individuals presenting with symptoms sug-
gestive of TB for identifying cases among those who are HIV un-
infected. This method was shown to miss a large proportion of
facility-based TB cases presenting at health facilities for reasons
other than respiratory symptoms.13 TB symptom screening tradi-
tionally relies on triaging patients based on the presence of pro-
longed cough. The World Health Organization (WHO) recently
developed a more sensitive but less specific screening tool based
on the presence of any of 4 symptoms (current cough, fever,
weight loss, or night sweats) for use among patients with HIV in
LMICs, which showed potential as part of a clinical scoring system
for prioritizing TB investigation among symptomatic individuals
in South Africa.14
Once referred for TB testing, suspects should go on to be tested
with Xpert MTB/RIF, which was rolled out in South Africa to
replace sputum smear microscopy in 2012 and reached an esti-
mated coverage of 80% in 2016.15 Those patients who are HIV
infected (or whose HIV status is unknown) and who receive a
negative Xpert result should then give a second sputum sample
investigated using TB culture, although adherence to the follow-
up test is poor.16
Figure 1. Modeled interventions.
-- 3The sensitivity and specificity of the chosen screening and
diagnostic algorithm determine the consequential costs of diag-
nosis and treatment along the TB care cascade and are therefore a
crucial consideration for priority-setting in a resource-constrained
health system. For this reason, the South African TB Think Tank,
which supports TB policy making, was tasked with carrying out a
model-based economic evaluation to prioritize among the alter-
native algorithms considered for inclusion in the latest National
Tuberculosis Plan (NTP). The status quo and intervention scenarios
considered in the analysis and the respective policy-defined
coverage targets are described in Figure 1.
Identifying Constraints Scenarios
Our approach was embedded within the strategic planning
cycle through the South African TB Think Tank, a body that re-
views evidence on TB interventions and was responsible for rec-
ommending those to be considered in the NTP.17 The TB Think
Tank were asked to identify the main constraints on TB case
detection. The process of elicitation and quantification of the
constraints has been described in detail elsewhere.18 The selection
process relied on a published framework2 and aimed to illustrate
the different forms that constraints might take in influencing the
priority-setting process for infectious disease control.
Three supply-side constraints on health system resources that
apply to TB service provision in the public sector in South Africa
were defined for incorporation in the model: (1) a financial
constraint, characterized as the size of the available TB budget; (2)
a (nonfinancial) exogenous human resources (HR) constraint,
characterized as the maximum full time equivalent of nursing staff
that can be employed nationally in the provision of TB services
(registered, enrolled, and specialized TB nurses supply virtually all
TB services in the government sector in the country); and (3) a
diagnostics purchasing constraint, characterized as the maximum
number of Xpert tests purchased annually by the TB program. The
latter was considered as a policy constraint internal to the vertical
TB budget, which is restricted by an arbitrary, a priori belief held
by policymakers on the viable number of tests per TB case
detected (National Department of Health, written personal
communication, August 2014).
For the budget and HR constraints, 3 possible scenarios were
considered: a more restrictive scenario, where resources over timeare assumed to be virtually “static,” their increase uniquely driven
by the underlying growth rate of gross domestic product and
population, respectively; a medium scenario, where static health
resources are reallocated to TB services for the period covered by
the 2017-2022 NTP to match the share of disease burden caused
by TB, reported at 15% by NDoH; and a least restrictive scenario,
where 15% of “dynamic” health resources that realize their full
growth potential is reallocated to TB over the same period. The
maximum potential growth in the TB budget was informed by a
fiscal space analysis, whereas the availability of nurse time for TB
was estimated from routine data on historical workforce growth.18
One single scenario was considered for the diagnostics constraint,
setting the limit to a ratio of 20 Xpert tests purchased for every TB
case diagnosed in the previous budgeting period. Details on how
all constraints were parameterized are published in Bozzani et al
(2018).18
Cost-Effectiveness Model
We used a mathematical model of TB transmission to estimate
the number of TB cases, TB mortality, and the use of TB services
under each of the intervention scenarios (intervention 1 being the
base case and interventions 2-10 exploring different combinations
of screening and diagnostic algorithms; see Fig. 1).19 The model
was calibrated for the year 2015 and cost projections were
generated for a 20-year period up to 2035 by attaching unit costs
to model outputs. Unit costs for the TB case-finding and diagnostic
interventions as well as for the routine TB services affected by the
policy changes were constructed using ingredients costing from
ongoing studies as well as from published sources (Table 1).18,20-23
Only costs incurred by health service providers were considered.
All costs are presented in 2016 US dollars, and a discount rate of
3% was applied to future costs.
Health benefits of the interventions were measured in terms of
the disability-adjusted life years (DALYs) averted by each inter-
vention compared to the base case. DALYs were calculated using
transmission model outputs, including deaths by age and year and
the annual population distribution across TB- and HIV-related
health states. Disability weights were derived from a multi-
country valuation,24 assuming (1) asymptomatic HIV (CD4 . 350)
equal to “generic uncomplicated disease” (0.054); (2) those with
active TB and either asymptomatic HIV or on ART experience the
Table 1. Unit costs of TB services and interventions.18
Intervention Description Unit Unit cost of
output (2016
US$)
Source
Nurse time 1 minute of professional nurses' time Per minute 0.34 Nicola Foster, unpublished XTEND
data
Inpatient day Cost of hospitalization Per bed-day 44.44 Edina Sinanovic, unpublished XTEND
data
OPD visit Nurse consultation, 12 minutes
average duration
per event 4.08 Nicola Foster, unpublished XTEND
data
IPT treatment One OPD visit a month (at half
cost as on HIV) 1 INH 1 Xpert
cost every year
per month 7.81 Salome Charalambous, written
personal communication, October
2016
First-line TB treatment Facility-based observation, 2 months
intensive phase; 4
months continuation phase
per patient month 21.43 Treatment regimens from The Aurum
Institute (2016).20 Drug prices from
National Department of Health's
master procurement catalog,April 8,
2016.21 Only 20% of patients are
treated under DOTS; the rest visit the
facility once a month to collect drugs
(Dr Lindiwe Mvusi, National
Department of Health, oral personal
communication, November 2016).
MDR-TB treatment 6 months intensive phase;
18 months continuation phase
per patient month 359.06 As for first-line treatment. From
Sinanovic et al (2015),22 40% of
patients are hospitalized during
intensive phase; the rest receive fully
decentralized treatment
TB diagnostics Sum of costs of first- and
second-line diagnostic tests,
including visits and antibiotics*
per person
diagnosed
53.65 Costs of first-line diagnostics from
Cunnama et al (2016),23 Costs of
monitoring tests from Edina
Sinanovic, unpublished XTEND data
WHO symptoms
screener
4 minutes of a professional nurse per suspect
screened
1.36 Nicola Foster, unpublished XTEND
data
Cough triage 1.3 minutes of professional nurse
asking cough question
per suspect
screened
0.68 MERGE trial
DOTS indicates directly observed treatment, short course; INH, isoniazid; IPT, isoniazid preventive therapy; MDR-TB, multidrug-Resistant tuberculosis; OPD, outpatient
department.
Note. Shaded activities represent interventions introduced or modified under the 2017-2022 National TB Plan, as opposed to routine services.
*Cost per person diagnosed calculated as a weighted average of the unit costs of each test from the XTEND trial, where the weights represent the probability of receiving
each test experienced by diagnosed patients in the XTEND cohort.
Adapted from Bozzani et al.18
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those with acquired immunodeficiency syndrome (AIDS,
CD4 , 200) experience the same disability whether or not they
have active TB (0.547). Remaining life expectancy was estimated
throughout the period considered in the analysis from the South
African life tables.25
Estimating ICERs
The model was first run to estimate costs and effects of scaling
up the interventions in the absence of constraints. The individual
constraints scenarios were then applied independently to the
model by reducing the intervention coverage such that the pro-
jected resource requirements remained below the constraint over
the entire analytic horizon. The cost-effectiveness of the in-
terventions was then assessed at the coverage that could be
achieved within the available resources. If target coverage was not
achieved, then a real constraint was identified and the model was
re-run at a reduced coverage, such that the projected resource
requirements remained below the constraint over the entire an-
alytic horizon. Budget requirements were estimated by thestandard economic model attaching unit costs to TB transmission
model outputs. HR requirements were similarly calculated by
attaching to model outputs an estimate of the nurse minutes
required to deliver the TB screening and diagnostic interventions
as well as the routine services along the TB care cascade.18 The
diagnostics constraint was incorporated as a multiplier in the
model, which limited intervention coverage once the set ratio of
Xpert tests to TB notifications was exceeded.
For those interventions that had to be delivered at a reduced
coverage under any of the HR constraint scenarios, the costs of
“relaxing” the constraint by adding extra nurses to the workforce
to achieve full coverage were calculated18 to produce a third set of
ICERs alongside the unconstrained and constrained ICERs. These
represent the true opportunity cost of delivering the in-
terventions. We assumed no additional health system investment
would be necessary for relaxing the financial and diagnostics
constraints (besides increasing the TB budget and purchasing
additional Xpert tests, respectively), so that the costs of achieving
full coverage would be equal to those predicted by the model
under the unconstrained scenario.
Table 2. Incremental costs, DALYs averted, and ICERs* for interventions 2 through 10 compared to intervention 1 (base case) under
selected constraint scenarios.
Intervention (target
coverage†)
Constraint
scenario
Incremental costs (US
dollars, thousands)
DALYs averted (
thousands)
Incremental cost per DALY
averted (US dollars)
2 (100% Xpert coverage) Unconstrained 334 654 299 1121
HR (least
limiting)
334 654 299 1121
HR (medium) 334 654 299 1121
Financial
(medium)
334 654 290 1153
Diagnostics 189 237 234 809
3 (90% follow-up of Xpert
negatives)
Unconstrained 73 201 86 847
HR (least
limiting)
73 201 86 847
HR (medium) 73 201 86 847
Financial
(medium)
73 201 86 847
Diagnostics 68 411 85 806
4 (2 1 3) Unconstrained 417 027 381 1093
HR (least
limiting)
417 027 381 1093
HR (medium) 417 027 381 1093
Financial
(medium)
417 027 381 1093
Diagnostics 268 375 318 844
5 (cough triage in 100% of
patients with HIV)
Unconstrained –496 799 34 –14 588
HR (least
limiting)
–496 799 34 –14 588
HR (medium) –496 799 34 –14 588
Financial
(medium)
–496 799 34 –14 588
Diagnostics –395 416 89 –4425
6 (cough triage in 90% PHC
patients)
Unconstrained 525 977 255 2061
HR (least
limiting)
525 514 255 2060
HR (medium) 126 528 56 2248
Financial
(medium)
525 977 255 2061
Diagnostics 91 886 46 1989
7 (WHO screener in 100% of
patients with HIV)
Unconstrained 2693 662 649 4148
HR (least
limiting)
1 359 565 420 3241
HR (medium) 130 455 52 2489
Financial
(medium)
2 693 662 649 4148
Diagnostics 128 738 56 2303
8 (WHO screener in 90% PHC
patients)
Unconstrained 3800 388 907 4190
HR (least
limiting)
463 344 27 17 201
HR (medium) 170 109 -78 –2193
Financial
(medium)
3 800 388 907 4190
Diagnostics –31 106 -102 304‡
9 (4 1 6) Unconstrained 988 363 620 1595
HR (least
limiting)
987 853 619 1595
HR (medium) 512 389 414 1237
Financial
(medium)
988 363 620 1595
Diagnostics 335 806 345 972
continued on next page
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Table 2. Continued
Intervention (target
coverage†)
Constraint
scenario
Incremental costs (US
dollars, thousands)
DALYs averted (
thousands)
Incremental cost per DALY
averted (US dollars)
10 (4 1 8) Unconstrained 4631 162 1,222 3789
HR (least
limiting)
932 298 401 2327
HR (medium) 606 355 303 2004
Financial
(medium)
4 606 292 1,220 3776
Diagnostics 123 317 212 582
DALYs indicate disability-adjusted life years; GDP, gross domestic product; HR: human resources; ICER, incremental cost-effectiveness ratio; PHC, primary healthcare.
Note. Dominant interventions shown on expansion path. Strongly (costlier, less effective than another individual intervention) and weakly (costlier, less effective than a
combination of nonmutually exclusive interventions) dominated interventions shown in lighter shade.
*Cumulative values for 20-year analytic horizon (2016-2035) discounted at 3% per year. All costs reported in 2016 US dollars.
†Target coverage refers to the coverage achievable under the unconstrained scenario.
‡Scenario produces negative costs and health benefits compared to base case. Reported ICER represents the costs and effects of moving from scenario to base case, as
opposed to the other comparisons.
Adapted from Bozzani et al (2018)18
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The incremental costs, DALYs averted, and ICERs compared to
base case for all the interventions under the unconstrained and
constrained scenarios (only for scenarios that had a realistic
impact on feasibility of one or more interventions) are presented
in Table 2. Detailed results on cost estimation and the effects of the
constraints on intervention impact have been presented
elsewhere.18,19
Cost-Effectiveness Ranking Without Constraints
Figure 2 presents the ICER ranking of intervention options on
the cost-effectiveness plane. Dominant options are shown on the
expansion path from intervention 1 (the base case) at the origin.
Interventions that are strongly (costlier and less effective than an
individual intervention) or weakly dominated (costlier and less
effective than a combination of nonmutually exclusive in-
terventions) are shown outside the expansion path. When supply-
side constraints are not taken into consideration (Fig. 2, panel A),
the option with the highest costs and the most DALYs averted
compared to the base case was intervention 10, the combination
of strengthening the diagnostic algorithm and screening 90% of all
patients in primary healthcare (PHC) using the WHO tool.
Assuming an indicative willingness-to-pay threshold equal to half
the gross domestic product per capita per DALY averted ($3044),
South Africa would adopt intervention 9 under this scenario,
combining the strengthening of the Xpert algorithm with use of
the less sensitive cough triage in the PHC population. This inter-
ventionwould require a twofold increase in the total TB budget for
South Africa for 2015.
Cost-Effectiveness Ranking With Constraints
The least limiting financial constraint was not exceeded by any
of the interventions, although the most limiting financial and HR
constraints were exceeded by almost all interventions at some
point during the analytical time horizon, indicating that any TB
case-finding policy change would not be feasible in South Africa
without some reprioritization of funds. The medium financial
constraint would cause a shortfall of approximately $25 million
over the period 2016-2035 and thus reduce overall intervention
effectiveness (Table 2).
Incorporating nonfinancial constraints influences the ranking
of interventions under the least restrictive and medium HR con-
straints (Fig. 2, panels B-C), as well as under the diagnostic
constraint. In these 3 scenarios, intervention 10 was (weakly)dominated by intervention 9 (combination of strengthened diag-
nostic algorithm and cough triage for screening PHC patients),
which became more effective than option 10 at reduced coverage
and had a lower ICER. The least restrictive and medium HR con-
straints had a substantial impact on the coverage of all ICF in-
terventions (6-10), except for the use of cough-based screening in
HIV clinics (5), which constitutes a reversal of the current guide-
lines recommending use of the WHO tool among patients with
HIV, adhered to in approximately 40% of cases.26 Overall, the di-
agnostics constraint caused the greatest reductions in the impact
of all intervention options involving the strengthening of the
diagnostic algorithm (interventions 2-4) as well as the expansion
of ICF to all PHC patients using any screening tool (interventions 6,
8, 9, and 10), due to the limit it placed on the consequential scaling
up of Xpert.
Cost-Effectiveness of Relaxing HR Constraints
Figure 2, Panels B2-C2 show the ICERs considering the health
system investment for training, hiring, and deploying the addi-
tional nurses required to deliver the interventions at the target
coverage. Once the constraints were relaxed, option 10 once again
displayed the highest ICER, as in the unconstrained scenario
(Fig. 2, panel A). Investing in the generation of extra HR capacity to
deliver the strengthened diagnostic andWHO screening algorithm
intervention at the desired coverage requires an increase of
approximately 60% in the TB service delivery budget during the
2016-2035 period compared with the current expenditure level
(from about $6.3 billion to $10 billion), and these additional costs
substantially decrease cost-effectiveness compared with the
threshold.Discussion
We demonstrate an empirical approach to incorporating
nonfinancial constraints into cost-effectiveness analysis that can
inform investment decisions where health sectors face resource
limitations or policy restrictions. In our case study, we illustrated
to decision makers the consequences of not addressing constraints
(reduced intervention impact) and the returns on investment in
removing them (costs of relaxing HR constraints). As such, we
present an approach that reflects an understanding of health
sectors facing complex short-run constraints and that allows
policy makers to explore combinations of investments and to
optimize between the short and long run.
Figure 2. Cost-effectiveness planes for selected constraints scenarios. (A) Unconstrained. (B) HR constraint (least limiting). (C) HR
constraint (medium). (D) HR, relaxed (least limiting). (E) HR, relaxed (medium).
-- 7The prior beliefs of policy makers around the potential lack of
feasibility of expanding HR-intensive ICF strategies that generate
high volumes of Xpert diagnostic tests further down the TB
cascade in an overstretched health system were reinforced by our
analysis. Critically, we find that, in the presence of HR constraints,
expanding the TB budget is not enough to achieve the desired
coverage target of ICF interventions. This highlights the impor-
tance of long-term investments in training and hiring more
nurses, as well as the presence of a time lag for deploying this
extra workforce, which in turn may impact intervention effect.
Our findings are in line with van Baal and colleagues, whose
theoretical model illustrated that, in the short term, choosing in-
terventions whose feasibility is more dependent on the avail-
ability of physical inputs such as HR has a higher opportunity cost
than choosing less resource-intensive options.1 Adding to van
Baal’s approach, the present work presents a possibility for
dealing with available routine data that are also independent of
specific opportunity cost thresholds. Moreover, it expands the
choice set by presenting the option of relaxing health system
constraints and, although not shown in the case study presented,
could accommodate an analysis of returns to scale for physical
inputs.
Despite being feasible, our approach has some potential limi-
tations and requires further development. First, although we
completed the analysis within a policy-defined time frame, it
required considerable additional effort compared to conventional
approaches. In particular, we had to obtain high-quality published
and unpublished cost data from previous studies in South Africa,
we gained access to and collated detailed data on HR supply, and
we spent considerable time defining constraints as well as dis-
cussing and deliberating with decision makers (TB Think Tank) on
how to represent them in the model. Our approach may thus beless feasible where data availability and formal planning struc-
tures are more limited. Second, our conclusions rely on the
assumption that, in the presence of constraints, existing TB ser-
vices would not be scaled back to accommodate new screening
interventions. Although rare in practice, decision makers might be
willing to consider divesting from existing activities to increase
coverage of desirable new interventions. Moreover, we have
assumed that there would be no interactions between the con-
straints, as they applied to different types of resources. But
because constrained inputs are all funded from the health budget,
interactions might occur, and thus the analysis would need to
apply the constraints to the model simultaneously and quantify
the extent of the interactions. Finally, we have considered a single
change in ICF coverage of screening in each scenario over time,
without acknowledging that policies are dynamic and responsive
to system changes.Conclusion
Despite its limitations, the approach presented earlier em-
phasizes the importance and feasibility of supplying decision
makers with information on the “real-world” cost-effectiveness
and performance of intervention options under different types
of health system constraints. In many LMICs, decisions on the
adoption of new technologies are coupled with scale-up decisions
and are not seen as separate processes. The further testing of
approaches such as the one presented here is required to ensure
that health sector decision makers can explore the optimal bal-
ance between short-run purchasing of new technologies and
long-term investment to reduce nonfinancial health systems
constraints.
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